265 related articles for article (PubMed ID: 18950880)
21. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
[TBL] [Abstract][Full Text] [Related]
22. Dose escalation for prostate cancer using the three-dimensional conformal dynamic arc technique: analysis of 542 consecutive patients.
Jereczek-Fossa BA; Vavassori A; Fodor C; Santoro L; Zerini D; Cattani F; Garibaldi C; Cambria R; Fodor A; Boboc GI; Vitolo V; Ivaldi GB; Musi G; de Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):784-94. PubMed ID: 18191332
[TBL] [Abstract][Full Text] [Related]
23. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial.
Koper PC; Jansen P; van Putten W; van Os M; Wijnmaalen AJ; Lebesque JV; Levendag PC
Radiother Oncol; 2004 Oct; 73(1):1-9. PubMed ID: 15465140
[TBL] [Abstract][Full Text] [Related]
24. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
[TBL] [Abstract][Full Text] [Related]
25. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison.
Leborgne F; Fowler J
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1441-6. PubMed ID: 19395194
[TBL] [Abstract][Full Text] [Related]
26. [Conformal radiotherapy to 76Gy in localized prostate cancer. Therapeutic modalities and preliminary results].
Pontvert D; Gaboriaud G; Flam T; Jourdan-Da Silva N; Thiounn N; Mammar H; Beuzeboc P; Debré B
Cancer Radiother; 2008 Mar; 12(2):78-87. PubMed ID: 18248831
[TBL] [Abstract][Full Text] [Related]
27. Definitive conformal radiotherapy for localized high-risk prostate cancer: a long-term follow-up study with PSA course.
Bruns F; Franzki C; Wegener G; Karstens JH
Anticancer Res; 2007; 27(4A):1847-51. PubMed ID: 17649783
[TBL] [Abstract][Full Text] [Related]
28. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
[TBL] [Abstract][Full Text] [Related]
29. 3D conformal radiation therapy for prostate cancer in elderly patients.
Geinitz H; Zimmermann FB; Thamm R; Schumertl A; Busch R; Molls M
Radiother Oncol; 2005 Jul; 76(1):27-34. PubMed ID: 15990188
[TBL] [Abstract][Full Text] [Related]
30. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect.
Zapatero A; García-Vicente F; Modolell I; Alcántara P; Floriano A; Cruz-Conde A; Torres JJ; Pérez-Torrubia A
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1343-51. PubMed ID: 15275719
[TBL] [Abstract][Full Text] [Related]
31. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.
De Meerleer G; Vakaet L; Meersschout S; Villeirs G; Verbaeys A; Oosterlinck W; De Neve W
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):777-87. PubMed ID: 15465194
[TBL] [Abstract][Full Text] [Related]
32. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
[TBL] [Abstract][Full Text] [Related]
33. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation.
Christie D; Denham J; Steigler A; Lamb D; Turner S; Mameghan H; Joseph D; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Spry NA; Tai KH; Wynne C; Duchesne G; Kovacev O; Francis L; Kramar A; D'Este C; Bill D
Radiother Oncol; 2005 Nov; 77(2):117-25. PubMed ID: 16271786
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy.
Nichol A; Chung P; Lockwood G; Rosewall T; Divanbiegi L; Sweet J; Toi A; Bayley A; Bristow R; Crook J; Gospodarowicz M; McLean M; Milosevic M; Warde P; Catton C
Radiother Oncol; 2005 Jul; 76(1):11-7. PubMed ID: 15990187
[TBL] [Abstract][Full Text] [Related]
35. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
[TBL] [Abstract][Full Text] [Related]
36. Grading-system-dependent volume effects for late radiation-induced rectal toxicity after curative radiotherapy for prostate cancer.
van der Laan HP; van den Bergh A; Schilstra C; Vlasman R; Meertens H; Langendijk JA
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1138-45. PubMed ID: 17931794
[TBL] [Abstract][Full Text] [Related]
37. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
[TBL] [Abstract][Full Text] [Related]
38. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
[TBL] [Abstract][Full Text] [Related]
39. Time course of late rectal toxicity after radiation therapy for prostate cancer.
Odrazka K; Dolezel M; Vanasek J; Vaculikova M; Zouhar M; Sefrova J; Paluska P; Vosmik M; Kohlova T; Kolarova I; Macingova Z; Navratil P; Brodak M; Prosvic P
Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):138-43. PubMed ID: 20038960
[TBL] [Abstract][Full Text] [Related]
40. Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control.
De Meerleer GO; Fonteyne VH; Vakaet L; Villeirs GM; Denoyette L; Verbaeys A; Lummen N; De Neve WJ
Radiother Oncol; 2007 Feb; 82(2):160-6. PubMed ID: 17222931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
